In the recent years, the US Food and Drug Administration (FDA) has approved several anti-PD-1 monoclonal antibodies (Abs) that include pembrolizumab, nivolumab and cemipilimab for use in more than 50 tumor indications [7]. Here, PDCD1 is linked to neoplasm.